Roche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, as the Swiss pharma attempts to breathe new life into the drug curren
A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown.
